maximum weight loss tirzepatide surmount trials for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide shows 47% greater weight
Description
This anatomical alteration likely resulted in reduced GIP secretion, while GLP-1 secretion may have remained intact, given that hypoglycemic episodes occurred several hours after ingestion of small liquid meals, suggesting an exaggerated insulin response possibly driven by GLP-1, unopposed by glucagon due to insufficient GIP activity
35 The base-case values served as the mean for these distributions
It wins on accessibility
Read the label every single time
